A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion

被引:115
作者
Liebowitz, LD
Ashbee, HR
Evans, EGV
Chong, Y
Mallatova, N
Zaidi, M
Gibbs, D
机构
[1] Giles Sci Inc, Santa Barbara, CA 93140 USA
[2] Univ Witwatersrand, Dept Med Microbiol, ZA-2000 Johannesburg, South Africa
[3] S African Inst Med Res, ZA-2000 Johannesburg, South Africa
[4] Univ Leeds, Div Microbiol, Mycol Reference Ctr, Leeds LS2 9JT, W Yorkshire, England
[5] Yonsei Univ, Coll Med, Severance Hosp, Dept Clin Pathol, Seoul, South Korea
[6] Hosp Ceske Budejovice, Dept Med Microbiol, Ceske Budejovice 37087, Czech Republic
[7] Hosp Gen OHoran, Dept Invest, Merida 97000, Mexico
关键词
D O I
10.1016/S0732-8893(01)00243-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The in-vitro activity of fluconazole against 46,831 yeast isolates collected over a two-year period from 57 laboratories in 33 countries worldwide was assessed using a disc diffusion method. Candida albicans was the organism isolated most frequently, accounting for 68.6% of the total number of isolates. C, glabrata, C, tropicalis, C parapsilosis and C. krusei and Cryptococcus neoformans represented 9.9, 4.7, 4.3, 1.9, and 1.4% of isolates respectively during the 2 year period and rates varied markedly between countries. In 1999 data blood isolates represented 4.9% of all isolates and intensive care unit isolates represented 9.9%, In both the 1998 and 1999 data, 99% of C, albicans were fully susceptible (S) to fluconazole, and 95.6% of all species of yeasts tested were S or susceptible-dose dependent (S-DD) to fluconazole. No emerging trends of resistance were noted with any of the Candida spp. tested as 96% of all isolates retained susceptibility (S or S-DD) to this agent. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 26 条
[21]   FLUCONAZOLE-RESISTANT CANDIDA-ALBICANS AFTER LONG-TERM SUPPRESSIVE THERAPY [J].
SANGUINETI, A ;
CARMICHAEL, JK ;
CAMPBELL, K .
ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (09) :1122-1124
[22]   CORRELATION BETWEEN IN-VITRO SUSCEPTIBILITY OF CANDIDA-ALBICANS AND FLUCONAZOLE-RESISTANT OROPHARYNGEAL CANDIDIASIS IN HIV-INFECTED PATIENTS [J].
TROILLET, N ;
DURUSSEL, C ;
BILLE, J ;
GLAUSER, MP ;
CHAVE, JP .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1993, 12 (12) :911-915
[23]   TREATMENT OF SYSTEMIC FUNGAL-INFECTIONS - RECENT PROGRESS AND CURRENT PROBLEMS [J].
WALSH, TJ ;
PIZZO, A .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1988, 7 (04) :460-475
[24]   HOSPITAL-ACQUIRED CANDIDEMIA - THE ATTRIBUTABLE MORTALITY AND EXCESS LENGTH OF STAY [J].
WEY, SB ;
MORI, M ;
PFALLER, MA ;
WOOLSON, RF ;
WENZEL, RP .
ARCHIVES OF INTERNAL MEDICINE, 1988, 148 (12) :2642-2645
[25]   AZOLE-RESISTANT CANDIDA-ALBICANS - REPORT OF 2 CASES OF RESISTANCE TO FLUCONAZOLE AND REVIEW [J].
WHITE, A ;
GOETZ, MB .
CLINICAL INFECTIOUS DISEASES, 1994, 19 (04) :687-692
[26]   Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing [J].
Witt, MD ;
Lewis, RJ ;
Larsen, RA ;
Milefchik, EN ;
Leal, MAE ;
Haubrich, RH ;
Richie, JA ;
Edwards, JE ;
Ghannoum, MA .
CLINICAL INFECTIOUS DISEASES, 1996, 22 (02) :322-328